Respiratory trials have a measurement problem. Too many tools. Too many vendors. Too many data gaps between clinic visits. Strados Labs is betting it can fix that—by owning the entire measurement stack.
In March 2026, Strados acquired the clinical trials division of NuvoAir. The goal is simple: One partner. Every respiratory endpoint. Zero handoffs.
Traditional respiratory trials rely heavily on clinic snapshots. But diseases like COPD and asthma don’t behave on a schedule. They fluctuate daily. Sometimes hourly. That’s where continuous, real-world data comes in.
This acquisition pushes Strados toward a new model:
The result? A closed-loop respiratory endpoint ecosystem—from Phase I to Phase IV.
With NuvoAir Clinical Trials integrated, the Strados Endpoint Suite now includes:
Together, these create: An end-to-end respiratory data pipeline with no fragmentation.
This deal reflects a broader industry transition: From episodic data → to continuous data streams
Here’s what changes:
|
Old Model |
New Model |
|
Clinic visits define data |
Daily life defines data |
|
Manual quality checks |
Real-time Validation |
|
Fragmented Vendors |
Single partner integration |
Strados is leaning hard into:
Translation: Data quality is built at the point of capture—not fixed later.
This isn’t a theoretical platform. It’s already battle-tested.
Key assets include:
This gives sponsors confidence in:
For pharma and CROs, this simplifies execution:
In practical terms: Fewer operational headaches. More reliable endpoints.
Nick Delmonico, CEO and co-founder of Strados, put it bluntly: Respiratory drug development depends on what happens between clinic visits—not just during them.
Meanwhile, Chris Skowronek emphasized the strategic fit:
The outcome: Expanded capabilities + sharper focus for both companies NuvoAir will now concentrate entirely on patient care.
Strados is maintaining continuity:
This matters: Because in clinical trials, disruption = risk.
This acquisition signals a clear direction for respiratory R&D: Endpoint consolidation is becoming a competitive advantage. Expect more moves like this. Why?
Because sponsors increasingly want:
Strados is positioning itself as: The “single source of truth” for respiratory endpoints.
This isn’t just an acquisition. It’s infrastructure. Strados is building a system where:
If it works at scale, it could redefine how respiratory trials are run. And more importantly— How respiratory drugs get approved, faster.